American Medical Writers Association

MedConnectUSA Awarded The ATSI Award Of Excellence 2023

Retrieved on: 
Wednesday, July 5, 2023
Award, ASTI, City centre, Patient, ATSI, Knowledge, American Medical Writers Association, System, Risk management, Pharmaceutical industry, Nursing

LAS VEGAS, July 5, 2023 /PRNewswire-PRWeb/ -- MedconnectUSA is honored to be awarded the coveted ATSI Award of Excellence for the eighteenth year in a row. Consistently being recognized for outstanding contributions to the medical answering service industry is something that the MedConnectUSA team is proud of.

Key Points: 
  • LAS VEGAS, July 5, 2023 /PRNewswire-PRWeb/ -- MedconnectUSA is honored to be awarded the coveted ATSI Award of Excellence for the eighteenth year in a row.
  • Winning the ATSI Award of Excellence 2023 means the world to everyone at MedConnectUSA.
  • Being awarded the ATSI Award of Excellence for the eighteenth year running in 2023 highlights MedConnectUSA's ongoing commitment to its clients and the medical answering service industry.
  • "Being awarded the ATSI Award of Excellence for the eighteenth year running in 2023 is an amazing accolade to receive.

Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training

Retrieved on: 
Monday, February 27, 2023
Organization, Knowledge, American Medical Writers Association, Digital, Nursing, Veeva Systems

UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management.

Key Points: 
  • UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management.
  • Turacoz Healthcare Solutions has fully embraced this shift, moving from traditional methods to a centralized and streamlined approach using Veeva.
  • Turacoz is now excited to launch a unique Certificate Course in Digital Content Lifecycle Management in March 2023.
  • By equipping individuals with the latest medical writing skills and tools, Turacoz is at the forefront of shaping the future of digital content management in healthcare communications.

Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training

Retrieved on: 
Monday, February 27, 2023
Organization, Knowledge, American Medical Writers Association, Digital, Nursing, Veeva Systems

UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management.

Key Points: 
  • UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management.
  • Turacoz Healthcare Solutions has fully embraced this shift, moving from traditional methods to a centralized and streamlined approach using Veeva.
  • Turacoz is now excited to launch a unique Certificate Course in Digital Content Lifecycle Management in March 2023.
  • By equipping individuals with the latest medical writing skills and tools, Turacoz is at the forefront of shaping the future of digital content management in healthcare communications.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Retrieved on: 
Thursday, July 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Plasma kallikrein, FDA, HAE, Clinical & Experimental Allergy, Patient, Joint FAO/WHO Expert Committee on Food Additives, G&A, Research, American Academy, AAAAI, DME, Hereditary angioedema, Marketing, COVID-19, European Commission, Company, U.S. Securities and Exchange Commission, Annual report, American Academy of Allergy, Asthma, and Immunology, D, Net, Forward-looking statement, KKS, Quarter, KALV, World, Security (finance), Royal commission, American Medical Writers Association, Risk, Private Securities Litigation Reform Act, NASDAQ, Form 10-K, Board, Diabetic retinopathy, Safety, Program, Director, Pharmaceutical industry, Information technology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2022.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2022.
  • The orphan designation allows KalVista guaranteed access to the centralized procedure for marketing authorization, among other benefits, and would provide 10 years of market exclusivity.
  • Research and development expenses were $70.2 million for the fiscal year ended April 30, 2022, compared to $41.3 million for the prior fiscal year.
  • General and administrative expenses were $26.4 million for the fiscal year ended April 30, 2022, compared to $16.6 million for the prior fiscal year.

KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

Retrieved on: 
Tuesday, May 17, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, WHO Expert Committee on Leprosy, U.S. Securities and Exchange Commission, Annual report, World, Patient, NASDAQ, Form 10-K, Hereditary angioedema, COVID-19, FDA, Forward-looking statement, Safety, Risk, NDA, Diabetic retinopathy, American Medical Writers Association, Private Securities Litigation Reform Act, HAE, Security (finance), DME, KALV, Pharmaceutical industry, Information technology

The KONFIDENT study continues to enroll on track with our expectations, and we have many other activities ongoing to prepare for the eventual NDA submission.

Key Points: 
  • The KONFIDENT study continues to enroll on track with our expectations, and we have many other activities ongoing to prepare for the eventual NDA submission.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need.
  • KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
  • KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks and has initiated the Phase 3 KONFIDENT clinical trial.

New Workforce Development Book Provides Solutions to Fill 10-Million Open Jobs

Retrieved on: 
Thursday, September 23, 2021
Well, Thought, Strategy, Health, Multimedia, Patient, Association, Amazon, Timea Majorová, Kaiser Permanente, Employment, CEO, National, Equifax Workforce Solutions, COVID, American Medical Writers Association, Federal Reserve Bank of Atlanta, Federal Reserve Bank, SEIU, Johns, View, National Governors Association, California Community Colleges, Ecosystem, Management

Drawing on her many years of experience in the private, public,and nonprofitsectors, including her timeas executive vice chancellor of the California Community Colleges, Ton-Quinlivan's book sharesacollection of proven workforce development strategies.

Key Points: 
  • Drawing on her many years of experience in the private, public,and nonprofitsectors, including her timeas executive vice chancellor of the California Community Colleges, Ton-Quinlivan's book sharesacollection of proven workforce development strategies.
  • "This book is great storytelling and a master class in big design thinking.Well worth reading,"statesTammy Johns, CEO of Strategy & Talent, former SVP Innovation and Workforce Solutions of ManpowerGroup.
  • If ever there was a time for theseinsights, it would be now.The book is now available forpurchase on Amazon .Book proceeds go to benefitFuturo Health'snonprofit mission.
  • We believe investing ineducation and skills training and retraining results in better-paying jobs for workers, betterservice for patients and better workers for employers to hire.